Piracetam-Darnitsa Solution for Injection, 200 mg/mL, 5 mL, No. 10

In stock: 1
$54.00

Ingredients

Active ingredient: piracetam;

1 tablet contains 400 mg of piracetam;

excipients: crystalline sugar, microcrystalline cellulose, potato starch, talc, colloidal anhydrous silicon dioxide, magnesium stearate.

Dosage Form

Tablets.

Main physical and chemical properties: tablets are white or white with a creamy tint; marbling is permitted; they have a flat surface, a bevel, and a score line.

Pharmacotherapeutic group

Psychostimulants and nootropics.

ATC code N06B X03.

Pharmacological properties

Pharmacodynamics.

Piracetam is a nootropic agent that acts on the brain, improving cognitive processes such as learning ability, memory, attention, and mental performance. Piracetam affects the central nervous system in various ways: by altering the speed of nerve impulse propagation in the brain, improving metabolic processes in nerve cells, enhancing microcirculation, and positively affecting blood rheological properties. However, it does not have a vasodilatory effect.

It improves connections between the brain’s hemispheres and synaptic conduction in subcortical structures. Piracetam inhibits platelet aggregation and restores the elasticity of the erythrocyte membrane, reducing erythrocyte adhesion. At a dose of 9.6 g, it reduces fibrinogen and von Willebrand factor levels by 30–40% and prolongs bleeding time. Piracetam exerts a protective and restorative effect in cases of impaired brain function due to hypoxia and intoxication. Piracetam reduces the severity and duration of vestibular nystagmus.

Pharmacokinetics.

After oral administration, piracetam is rapidly and almost completely absorbed, with peak plasma concentrations reached 1 hour after administration. Bioavailability is approximately 100% following a single 2-g dose. The volume of distribution of piracetam is approximately 0.6 L/kg. The half-life of the drug in plasma is 4–5 hours and 8.5 hours in cerebrospinal fluid, which is prolonged in renal insufficiency. It does not bind to plasma proteins and is not metabolized in the body. 80–100% of piracetam is excreted by the kidneys in its unchanged form via renal filtration. The renal clearance of piracetam in healthy volunteers is 86 mL/min. The pharmacokinetics of piracetam are not altered in patients with hepatic insufficiency. Piracetam crosses the blood-brain and placental barriers, as well as the membranes used in hemodialysis.

Indications

Adults:

  • symptomatic treatment of pathological conditions accompanied by memory impairment and cognitive disorders, with the exception of diagnosed dementia;
  • treatment of cortical myoclonus, either as monotherapy or as part of combination therapy.

Contraindications

Hypersensitivity to piracetam or pyrrolidone derivatives, as well as to other components of the drug.

Acute cerebrovascular accident (hemorrhagic stroke).

End-stage renal failure.

Huntington’s chorea.

Interactions with Other Medications and Other Types of Interactions

Thyroid hormones.

When used concomitantly with thyroid hormones, increased irritability, disorientation, and sleep disturbances may occur.

Acenocoumarol.

Clinical studies have shown that in patients with severe recurrent thrombosis, the use of piracetam in high doses (9.6 g/day) did not affect the acenocoumarol dosage required to achieve a prothrombin time (INR) of 2.5–3.5; however, when used concomitantly, a significant reduction was observed in platelet aggregation, fibrinogen levels, von Willebrand factor (coagulation activity (VIII: C); ristocetin cofactor (VIII: vW: Rco) and plasma protein (VIII: vW: Ag;)), as well as blood and plasma viscosity.

Pharmacokinetic interactions.

The likelihood of changes in the pharmacodynamics of piracetam under the influence of other drugs is low, since 90% of the drug is excreted unchanged in the urine.

In vitro, piracetam does not inhibit the cytochrome P450 isoforms CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 4A9/11 at concentrations of 142, 426, and 1,422 μg/mL.

At a concentration of 1,422 μg/mL, slight inhibition of CYP2A6 (21%) and CYP4A9/11 (11%) was observed. However, the Ki values for these two CYP isomers are sufficient at concentrations exceeding 1,422 μg/mL. Therefore, metabolic interactions with drugs that undergo biotransformation by these enzymes are unlikely.

Antiepileptic drugs.

Administration of piracetam at a dose of 20 g daily for 4 weeks or longer did not alter the concentration-time curve or the maximum concentration (Cmax) of antiepileptic drugs in serum (carbamazepine, phenytoin, phenobarbital, sodium valproate) in patients with epilepsy.

Alcohol.

Concomitant use with alcohol did not affect the serum concentration of piracetam, and serum alcohol concentration remained unchanged following a single 1.6 g dose of piracetam.

In the elderly, piracetam enhances the effects of antianginal agents and increases the efficacy of antidepressants.

Special Considerations for Use

Effect on platelet aggregation.

Since piracetam reduces platelet aggregation (see the “Pharmacological Properties” section), this medication should be prescribed with caution to patients with hemostatic disorders, conditions that may be accompanied by bleeding (gastrointestinal ulcers), during major surgical procedures (including dental procedures), to patients with symptoms of severe bleeding, or to patients a history of hemorrhagic stroke; and patients taking anticoagulants or antiplatelet agents, including low doses of acetylsalicylic acid. The drug is excreted by the kidneys; therefore, special attention should be given to patients with renal insufficiency.

Elderly patients.

During long-term therapy in elderly patients, regular monitoring of renal function is recommended; if necessary, the dose should be adjusted based on the results of creatinine clearance testing (see the “Dosage and Administration” section). It passes through the filtration membranes of hemodialysis machines.

When treating patients with cortical myoclonus, abrupt discontinuation of treatment should be avoided due to the risk of myoclonus generalization or the onset of seizures.

This medication contains crystalline sugar as an excipient, which should be taken into account by patients with diabetes mellitus.

Use during pregnancy or breastfeeding.

Pregnancy. There are no data on the use of piracetam in pregnant women. Results of preclinical studies do not indicate any direct or indirect harmful effects on the course of pregnancy, embryonic or fetal development, or the postnatal development of the child.

Piracetam crosses the placental barrier. The concentration of the drug in newborns ranges from 70% to 90% of its concentration in the mother. Piracetam should not be used during pregnancy unless absolutely necessary, except in cases where the pregnant woman’s clinical condition requires treatment with piracetam and the expected benefit to the mother outweighs the risk to the fetus.

Breastfeeding. Piracetam is excreted in breast milk. It should not be used while breastfeeding; if use of the drug is necessary, breastfeeding should be discontinued. A decision must be made regarding whether to discontinue breastfeeding or to discontinue piracetam therapy, taking into account the benefits of breastfeeding for the infant and the benefits of therapy for the woman.

Fertility. There are no clinical data on the effect of piracetam on fertility. Results from preclinical studies show that piracetam does not affect fertility in male and female rats.

Effect on reaction time when driving or operating machinery.

Caution should be exercised when driving or operating machinery due to the potential for adverse reactions affecting the central nervous system.

Dosage and Administration

Administer the medication orally with a small amount of water.

This medication is intended for adults.

Treatment of conditions accompanied by memory impairment and cognitive disorders.

The initial daily dose is 4.8 g during the first week of treatment. The dose is usually divided into 2–3 doses. The maintenance dose is 2.4 g per day. Subsequently, the dose may be gradually reduced by 1.2 g per day.

Treatment of cortical myoclonus.

The initial daily dose is 24 g for 3 days. If the desired therapeutic effect is not achieved during this time, continue administering the drug at the same dosage (24 g per day) for up to 7 days. If the desired therapeutic effect is not achieved by the 7th day of treatment, treatment should be discontinued. If a therapeutic effect has been achieved, then starting from the day when a sustained improvement is observed, begin reducing the dose of the medication by 1.2 g of piracetam every 2 days until symptoms of cortical myoclonus reappear. This will allow the determination of the average effective dose. The daily dose should be divided into 2–3 doses.

Treatment with other antimyoclonic agents should be continued at the previously prescribed doses. Continue treatment until the symptoms of the disease disappear. To prevent a worsening of the patient’s condition, do not abruptly discontinue the medication. Gradually reduce the dose by 1.2 g of piracetam every 2–3 days. Every 6 months, repeat courses of treatment with the drug should be prescribed, adjusting the dose based on the patient’s condition, until the symptoms of the disease disappear or diminish.

Elderly patients.

Dose adjustment is recommended for elderly patients with diagnosed or suspected renal impairment (see the “Patients with Renal Impairment” section). During treatment, creatinine clearance should be monitored to allow for appropriate dose adjustment in these patients as needed.

Patients with Impaired Renal Function.

Since the drug is excreted by the kidneys, caution should be exercised when treating patients with renal insufficiency.

An increase in the half-life is directly related to impaired renal function and creatinine clearance. This also applies to elderly patients, in whom creatinine clearance depends on age. The dosing interval should be adjusted based on the degree of renal impairment.

The dose should be calculated based on an estimate of the patient’s creatinine clearance. Calculate using the following formula:

Creatinine clearance = [140 – age (in years)] × body weight (kg) . (× 0.85 for women)
72 × plasma creatinine concentration (mg/dL)

Treatment for such patients should be prescribed based on the severity of renal insufficiency, following these recommendations:

Stage of renal insufficiency Creatinine clearance (mL/min) Dosage
No renal insufficiency > 80 Usual dose, divided into 2 or 4 doses
Mild 50–79 2/3 of the usual dose in 2–3 doses
Moderate 30–49 1/3 of the usual dose in 2 doses
Severe < 30 1/6 of the usual dose as a single dose
End-stage − Contraindicated

Patients with impaired liver function.

No dose adjustment is necessary for patients with hepatic impairment alone. In cases of diagnosed or suspected liver or kidney dysfunction, adjust the dose as described in the section “Patients with Renal Impairment.”

Children.

Do not use.

Overdose

Symptoms: increased severity of the drug’s side effects. Symptoms of overdose have been observed following oral administration of a 75 g dose of the drug.

Treatment is symptomatic. There is no specific antidote; hemodialysis may be used (removal of 50–60% of piracetam).

Side Effects

Frequency is defined as follows: very common (≥ 1/10), common (≥ 1/100 < 1/10), uncommon (≥ 1/1,000 < 1/100), rare (≥ 1/10,000 < 1/1,000), very rare (<1/10,000), isolated cases (frequency cannot be estimated from the available data).

System or organ according to the WHO System of Organ and System Classification Common

(≥1/100 to <1/10)

Uncommon

(≥1/1,000 to <1/100)

Nervous system disorders Hyperkinesia
Metabolic and nutritional disorders Weight gain
Mental disorders Anxiety Depression
General disorders Asthenia

Adverse reactions observed during postmarketing surveillance are listed below by organ system.

Ear and vestibular system disorders.

Rare cases: dizziness.

Gastrointestinal system.

Rare cases: abdominal pain, upper abdominal pain, diarrhea, nausea, vomiting.

Nervous system.

Common: hyperkinesia.

Uncommon: drowsiness.

Rare cases: ataxia, loss of balance, increased frequency of epileptic seizures, headache, insomnia, tremor.

Psychiatric disorders.

Common: nervousness.

Uncommon: depression.

Rare cases: increased excitability, anxiety, confusion, hallucinations.

Blood and lymphatic system disorders.

Rare cases: hemorrhagic disorders.

Immune system disorders.

Rare cases: hypersensitivity reactions, anaphylactoid reactions.

Skin and subcutaneous tissue disorders.

Rare cases: angioedema, dermatitis, rash, hives, itching.

Reproductive system and breast function.

Rare cases: increased sexual activity.

Investigations.

Common: weight gain.

Shelf life

3 years.

Storage conditions

Store in the original packaging out of the reach of children at a temperature not exceeding 25 °C.

Packaging

10 tablets per blister pack; 3 blister packs per package.

Dispensing Category

By prescription only.

Manufacturer

PJSC “Darnitsa Pharmaceutical Company.”